Rocephin and Pathological fracture - a phase IV clinical study of FDA data

Summary:

Pathological fracture is reported as a side effect among people who take Rocephin (ceftriaxone sodium), especially for people who are female, 60+ old, also take Zometa, and have Breast cancer.

The phase IV clinical study analyzes which people have Pathological fracture when taking Rocephin. It is created by eHealthMe based on reports of 15,458 people who have side effects when taking Rocephin from the FDA, and is updated regularly.

What is Rocephin?

Rocephin has active ingredients of ceftriaxone sodium. It is often used in infection. eHealthMe is studying from 15,665 Rocephin users. Check the latest studies of Rocephin.

What is Pathological fracture?

Pathological fracture (broken bone caused by disease) is found to be associated with 836 drugs and 541 conditions by eHealthMe. Check the latest studies of Pathological fracture.

On Jul, 05, 2026

15,458 people reported to have side effects when taking Rocephin.
Among them, 45 people (0.29%) have Pathological fracture.

$Could Rocephin cause Pathological fracture?$

Among these 45 people:

What is the gender of people who have Pathological fracture when taking Rocephin? *

female: 86.36 %
male: 13.64 %

What is the age of people who have Pathological fracture when taking Rocephin? *

What are other drugs people take besides Rocephin? *

What are other side effects people have besides Pathological fracture? *

Osteonecrosis Of Jaw (death of bone of jaw): 36 people, 80.00%
Fatigue (feeling of tiredness): 30 people, 66.67%
Stress And Anxiety: 28 people, 62.22%
Osteomyelitis (infection of bone): 27 people, 60.00%
Pleural Effusion (water on the lungs): 26 people, 57.78%
Depression: 25 people, 55.56%
Pain: 25 people, 55.56%
High Blood Pressure: 24 people, 53.33%
Atelectasis (partial or complete collapse of the lung): 24 people, 53.33%
Neuropathy Peripheral (surface nerve damage): 24 people, 53.33%

What are the existing conditions these people have? *

Breast Cancer: 20 people, 44.44%
Metastases To Bone (cancer spreads to bone): 15 people, 33.33%
Stress And Anxiety: 6 people, 13.33%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 11.11%
Fatigue (feeling of tiredness): 5 people, 11.11%
Nausea (feeling of having an urge to vomit): 4 people, 8.89%
Multiple Myeloma (cancer of the plasma cells): 3 people, 6.67%
Bone Loss: 3 people, 6.67%
Osteoporosis (bones weak and more likely to break): 3 people, 6.67%
Neoplasm Malignant (cancer tumour): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Rocephin and have Pathological fracture?

- Check whether Pathological fracture is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rocephin:

Rocephin (15,665 reports)

Browse all side effects of Rocephin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pathological fracture:

Pathological fracture (836 drugs)

Browse all the conditions that are associated with Pathological fracture:

Pathological fracture (541 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Rocephin) and Rocephin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.